Ozmosi | RC-28-E Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

RC-28-E

Alternative Names: rc-28-e, rc-28, rc 28, rc28, RC-28E, RC28E, RC 28E
Clinical Status: Active
Latest Update: 2025-11-26
Latest Update Note: News Article

Product Description

a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) for the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04782128)

Mechanisms of Action: VEGF Blocker, FGFR2 Blocker

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Rongchang Biopharmaceuticals (Yantai) Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RC-28-E

Countries in Clinic: China

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Macular Edema|Wet Macular Degeneration

Phase 2: Diabetic Retinopathy

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20202586

CTR20202586

P2

Completed

Diabetic Retinopathy

2024-07-05

2025-04-29

Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT05885503

28C005

P3

Recruiting

Macular Edema

2026-06-01

11%

2023-09-06

CTR20230065

CTR20230065

P3

Completed

Wet Macular Degeneration

2025-11-13

2025-12-14

Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status